|
Real-time Estimate
Cboe BZX
00:54:54 28/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 813.16 USD | -0.20% |
|
-1.61% | +5.37% |
| 02:48pm | AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial | RE |
| 08-25 | Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients | MT |
| Market Cap | 81.36B 69.84B 65.39B 59.87B 113B 7,771B 113B 774B 303B 3,916B 305B 299B 12,961B | P/E 2026 * |
18.9x | P/E 2027 * | 16.2x |
|---|---|---|---|---|---|
| Enterprise Value | 74.49B 63.94B 59.87B 54.82B 103B 7,115B 104B 709B 277B 3,586B 280B 274B 11,867B | EV / Sales 2026 * |
4.4x | EV / Sales 2027 * | 3.84x |
| Free-Float |
71.06% | Yield 2026 * |
0.48% | Yield 2027 * | 0.54% |
Last Transcript : Regeneron Pharmaceuticals, Inc.
| 1 day | -0.20% | ||
| 1 week | -1.61% | ||
| Current month | +6.64% | ||
| 1 month | +21.90% | ||
| 3 months | +29.56% | ||
| 6 months | +4.05% | ||
| Current year | +5.37% |
| 1 week | 804.27 |  | 847 |
| 1 month | 676.46 | | 847 |
| Current year | 591.52 | | 847 |
| 1 year | 541 | | 847 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 19/8/26 | Fiscal year | General Counsel | 33,583 | 0.0326% | ||
| 18/8/26 | Fiscal year | Chief Financial Officer | 17,165 | 0.0167% | ||
| 10/8/26 | Fiscal year | Director | 1,200 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.20% | -1.61% | +38.56% | -2.12% | 81.36B | |
| -5.65% | +5.87% | +462.35% | +24.00% | 59.75B | |
| +0.84% | +4.44% | -19.19% | -35.11% | 59.19B | |
| +0.76% | +3.53% | +0.08% | +36.18% | 53.33B | |
| +0.41% | +1.84% | +10.29% | +170.02% | 49.09B | |
| -0.02% | +3.28% | +62.36% | -16.47% | 32.66B | |
| -0.59% | +0.37% | +50.51% | +96.96% | 25.97B | |
| -2.00% | +9.52% | +12.38% | +218.34% | 24.39B | |
| +0.78% | +0.47% | +61.53% | +123.40% | 16.91B | |
| -4.68% | +2.52% | -9.33% | +752.25% | 15.64B | |
| Average | -1.02% | +0.21% | +66.95% | +136.75% | 41.83B | |
| Weighted average by Cap. | -0.87% | -0.95% | +82.91% | +73.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.92B 14.53B 13.6B 12.45B 23.46B 1,616B 23.52B 161B 62.95B 815B 63.53B 62.16B 2,696B | 18.42B 15.81B 14.8B 13.55B 25.53B 1,759B 25.6B 175B 68.52B 887B 69.15B 67.66B 2,934B |
| Net income | 4.77B 4.1B 3.84B 3.51B 6.62B 456B 6.64B 45.43B 17.76B 230B 17.92B 17.53B 760B | 5.45B 4.67B 4.38B 4.01B 7.55B 520B 7.57B 51.82B 20.26B 262B 20.44B 20B 867B |
| Net Debt | -6.87B -5.9B -5.52B -5.05B -9.52B -656B -9.55B -65.36B -25.55B -331B -25.79B -25.23B -1,094B | -10.55B -9.06B -8.48B -7.77B -14.63B -1,008B -14.67B -100B -39.26B -508B -39.62B -38.77B -1,681B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/08/26 | US$813.31 | -0.18% | 264,405 |
| 26/08/26 | US$814.79 | -2.25% | 585,370 |
| 25/08/26 | US$833.56 | +0.61% | 505,424 |
| 24/08/26 | US$828.50 | -0.66% | 672,012 |
| 21/08/26 | US$834.04 | +0.90% | 786,921 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
